These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
159 related articles for article (PubMed ID: 11215195)
1. [Clinical evaluation of urinary basic fetoprotein and the BTA test for detection of bladder cancer]. Imamura M; Inoue K; Megumi Y; Nishimura M; Ohmori K; Nishimura K Hinyokika Kiyo; 2000 Oct; 46(10):705-9. PubMed ID: 11215195 [TBL] [Abstract][Full Text] [Related]
2. [Urinary tumor marker for urothelial cancer]. Ohtani M; Iwasaki A; Shiraiwa H Gan To Kagaku Ryoho; 2001 Nov; 28(12):1933-7. PubMed ID: 11729491 [TBL] [Abstract][Full Text] [Related]
3. Comparative evaluation of the diagnostic performance of the BTA stat test, NMP22 and urinary bladder cancer antigen for primary and recurrent bladder tumors. Giannopoulos A; Manousakas T; Gounari A; Constantinides C; Choremi-Papadopoulou H; Dimopoulos C J Urol; 2001 Aug; 166(2):470-5. PubMed ID: 11458049 [TBL] [Abstract][Full Text] [Related]
4. [Quantification of bladder tumor antigen (BTA trak) and its correlation with bladder cancer grade and stage]. Rodríguez Martínez JJ; Escaf Barmadah S; Allende MT; Raigoso P; Martín Benito JL; Pérez García FJ; Fernández Gómez JM Arch Esp Urol; 2000; 53(1):1-6. PubMed ID: 10730418 [TBL] [Abstract][Full Text] [Related]
6. [Bladder tumor antigen test versus urinary cytology in patients with bladder tumors]. Gregersen B; Mommsen S; Svanholm H Ugeskr Laeger; 1999 Apr; 161(14):2071-3. PubMed ID: 10354792 [TBL] [Abstract][Full Text] [Related]
7. [Clinical evaluation of the bladder tumor marker "Tu-MARK-BTA"]. Yogi S; Ikeuchi T; Yoshikawa H; Hamashima T; Sasaki H; Morikawa F; Onodera Y; Matsumoto K; Kai Y Hinyokika Kiyo; 1991 Apr; 37(4):335-9. PubMed ID: 1891992 [TBL] [Abstract][Full Text] [Related]
8. The dilemma of suspicious urine cytology in patients being followed for bladder cancer. Raitanen MP; Aine R; Kylmälä T; Kallio J; Liukkonen T; Tammela T; Ann Chir Gynaecol; 2001; 90(4):256-9. PubMed ID: 11820413 [TBL] [Abstract][Full Text] [Related]
9. [The BTA stat test in the follow-up for bladder cancer]. Gutiérrez Baños JL; Martín García B; de Diego Rodríguez E; Hernández Rodríguez R; Portillo Martín JA; Correas Gómez MA; del Valle Schaan JI; Roca Edreira A; Rado Velázquez MA Arch Esp Urol; 1999 Oct; 52(8):856-61. PubMed ID: 10589117 [TBL] [Abstract][Full Text] [Related]
10. [Clinical evaluation of urinary nuclear matrix protein 22 as a marker for bladder cancer]. Kurokawa S; Morita T; Muraishi O; Tokue A Hinyokika Kiyo; 2001 Apr; 47(4):247-50. PubMed ID: 11411098 [TBL] [Abstract][Full Text] [Related]
11. Urinary cytology and quantitative BTA and UBC tests in surveillance of patients with pTapT1 bladder urothelial carcinoma. Babjuk M; Soukup V; Pesl M; Kostírová M; Drncová E; Smolová H; Szakacsová M; Getzenberg R; Pavlík I; Dvorácek J Urology; 2008 Apr; 71(4):718-22. PubMed ID: 18387400 [TBL] [Abstract][Full Text] [Related]
12. [Usefulness of BTA Stat test (Bard) in the diagnosis of bladder cancer. Preliminary results and comparison with cytology and cystoscopy]. Gutiérrez Baños JL; Martín García B; Hernández Rodríguez R; Portillo Martín JA; Correas Gómez MA; del Valle Schaan JI; Roca Edreira A; Villanueva Peña A; Gutíerrez García R; De Diego Rodríguez E; Rado Velázquez MA Arch Esp Urol; 1998 Oct; 51(8):778-82. PubMed ID: 9859583 [TBL] [Abstract][Full Text] [Related]
13. Routine follow-up cystoscopy in detection of recurrence in patients being monitored for bladder cancer. Raitanen MP; Leppilahti M; Tuhkanen K; Forssel T; Nylund P; Tammela T; Ann Chir Gynaecol; 2001; 90(4):261-5. PubMed ID: 11820414 [TBL] [Abstract][Full Text] [Related]
14. A side by side comparison of cytology and biomarkers for bladder cancer detection. Schroeder GL; Lorenzo-Gomez MF; Hautmann SH; Friedrich MG; Ekici S; Huland H; Lokeshwar V J Urol; 2004 Sep; 172(3):1123-6. PubMed ID: 15311054 [TBL] [Abstract][Full Text] [Related]
15. [Screening methods in the detection of bladder cancer: comparison of nuclear matrix protein-22, bladder tumor antigen and cytological examinations]. Fukui Y; Samma S; Fujimoto K; Akiyama T; Yamaguchi A; Hirayama A Hinyokika Kiyo; 2001 May; 47(5):311-4. PubMed ID: 11433750 [TBL] [Abstract][Full Text] [Related]
16. Comparative evaluation of the nuclear matrix protein, fibronectin, urinary bladder cancer antigen and voided urine cytology in the detection of bladder tumors. Eissa S; Swellam M; Sadek M; Mourad MS; El Ahmady O; Khalifa A J Urol; 2002 Aug; 168(2):465-9. PubMed ID: 12131289 [TBL] [Abstract][Full Text] [Related]
17. Comparative predictive values of urinary cytology, urinary bladder cancer antigen, CYFRA 21-1 and NMP22 for evaluating symptomatic patients at risk for bladder cancer. Sánchez-Carbayo M; Urrutia M; Silva JM; Romaní R; De Buitrago JM; Navajo JA J Urol; 2001 May; 165(5):1462-7. PubMed ID: 11342897 [TBL] [Abstract][Full Text] [Related]
18. Comparison of the Bard BTA test with voided urine and bladder wash cytology in the diagnosis and management of cancer of the bladder. Leyh H; Hall R; Mazeman E; Blumenstein BA Urology; 1997 Jul; 50(1):49-53. PubMed ID: 9218018 [TBL] [Abstract][Full Text] [Related]
19. [Tumor bladder antigen (TBA). A new method for the diagnosis and detection of recurrence of bladder cancer]. Escaf Barmadah S; Martín Benito JL; Fernández Gómez JM; San Martín Blanco A; Pérez Gracia FJ; Rodríguez Martínez JJ Arch Esp Urol; 1998 Mar; 51(2):129-36. PubMed ID: 9586309 [TBL] [Abstract][Full Text] [Related]
20. Four bladder tumor markers have a disappointingly low sensitivity for small size and low grade recurrence. Boman H; Hedelin H; Holmäng S J Urol; 2002 Jan; 167(1):80-3. PubMed ID: 11743280 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]